Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC + JS001 in HER2-Positive Solid Tumors
NCT04280341Phase 1Unknown
- Sponsor
- Peking University
- Start
- Jun 2020
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of disitamab vedotin in HER2-positive solid tumor, sponsored by Peking University. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximal Tolerance Dose at 28 days and 1 more. Status: unknown.
02
Drugs
disitamab vedotin
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT04280341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04280341.